Oppenheimer & Co. Inc. Cuts Stock Position in Abrdn Life Sciences Investors (NYSE:HQL)

Oppenheimer & Co. Inc. decreased its position in shares of Abrdn Life Sciences Investors (NYSE:HQL) by 19.0% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 19,598 shares of the company’s stock after selling 4,588 shares during the period. Oppenheimer & Co. Inc.’s holdings in Abrdn Life Sciences Investors were worth $296,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently bought and sold shares of HQL. Cetera Investment Advisers lifted its position in Abrdn Life Sciences Investors by 6.9% during the second quarter. Cetera Investment Advisers now owns 156,384 shares of the company’s stock valued at $2,216,000 after purchasing an additional 10,137 shares during the period. Advisors Asset Management Inc. raised its stake in shares of Abrdn Life Sciences Investors by 21.2% during the 1st quarter. Advisors Asset Management Inc. now owns 149,184 shares of the company’s stock valued at $2,033,000 after buying an additional 26,107 shares during the last quarter. Cetera Advisors LLC acquired a new position in shares of Abrdn Life Sciences Investors in the 1st quarter valued at about $1,929,000. 180 Wealth Advisors LLC boosted its stake in shares of Abrdn Life Sciences Investors by 2.8% in the second quarter. 180 Wealth Advisors LLC now owns 136,231 shares of the company’s stock worth $2,013,000 after buying an additional 3,682 shares during the last quarter. Finally, Blue Bell Private Wealth Management LLC grew its holdings in Abrdn Life Sciences Investors by 97.6% during the second quarter. Blue Bell Private Wealth Management LLC now owns 62,244 shares of the company’s stock worth $882,000 after acquiring an additional 30,750 shares during the period. Hedge funds and other institutional investors own 32.21% of the company’s stock.

Abrdn Life Sciences Investors Stock Performance

Abrdn Life Sciences Investors stock opened at $13.79 on Friday. Abrdn Life Sciences Investors has a 12 month low of $11.62 and a 12 month high of $15.90. The stock’s 50 day simple moving average is $14.93 and its two-hundred day simple moving average is $14.67.

Abrdn Life Sciences Investors Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, January 10th. Stockholders of record on Thursday, November 21st will be given a $0.50 dividend. This is a positive change from Abrdn Life Sciences Investors’s previous quarterly dividend of $0.49. The ex-dividend date is Thursday, November 21st. This represents a $2.00 annualized dividend and a dividend yield of 14.51%.

Abrdn Life Sciences Investors Company Profile

Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries.